MRK - NovoCure: TTFields Generating Revenues And Creating Avenues For Further Growth

• NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields.
• Its product has reached maturity phase in core active markets, with an expansion in new geographies on the cards.
• The healthcare equipment play is investing heavily in research and obtaining the FDA's designation as a breakthrough device for liver cancer is a positive.
• There may be short-term volatility towards the end of this quarter as expansion plans take time to deliver and R&D expenses continue to increase.
• In view of opportunities to expand and financial capability to develop new uses for TTFields, the stock is a buy at current prices.

For further details see: